Total
0
Shares
PainChek (ASX:PCK) - CEO, Philip Daffas
CEO, Philip Daffas
Source: PainChek
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PainChek (PCK) has delivered yet another quarter of positive growth for its namesake pain assessment and monitoring application
  • The technology works by recording a video of the user’s face and analysing it to recognise muscle movements that indicate pain
  • Once again, the app has proven successful in Australian residential aged care facilities by seeing a 61 per cent year-on-year growth in contracted facilities
  • In addition, the Morrison government has shown its support to expand the PainChek application to people’s homes to encourage the elderly to stay at home for as long possible
  • Most notably, PainChek received CE Mark and Therapeutic Goods Administration (TGA) approval to sell the PainChek app in the U.K., Australia and Europe
  • Rollout is commencing in Australia and the U.K. from this month with Europe to follow
  • At the end of the quarter, PainChek had $11.9 million in the bank
  • Company shares are down 4.55 per cent and are trading at 6.3 cents

Over the March 2021 quarter, PainChek (PCK) expanded sales in Australia as well as its overseas presence.

The healthcare stock is known for developing the world’s first smart phone-based pain assessment and monitoring application.

Essentially, the namesake technology works by using a camera to record a video of the user’s face and analyse it to recognise facial muscle movements that indicate pain.

A big achievement of the last quarter was receiving CE Mark and Therapeutic Goods Administration (TGA) approval to market and sell its expanded PainChek app in the U.K., Australia and Europe.

The roll-out is expected to begin from this month and will first focus on Australia and the U.K., before moving on to Europe.

The universal app has proven to be increasingly successful in Australian residential aged care facilities by seeing a 12 per cent growth compared to the prior quarter and 61 per cent growth year-on-year.

PainChek now has 288 aged care providers as clients, 993 contracted aged care facilities and 80,037 approved beds under an annual PainChek licence as of March 31 2021.

Significantly, these domestic sales represent more than 36 per cent of the Australian residential aged care market.

Moreover, the company’s Australian presence was expanded further due to it hosting more than 3000 virtual workshops to aged care providers across the country. Combined with the PainChek online learning curriculum, over 4400 aged care clinicians have been trained and conducted a PainChek assessment.

In addition to aged care homes, the Morrison government has shown its support to expand the PainChek application to homes. This will allow and encourage people to remain at home for as long possible and more funding is expected to be provided in June.

“Our goal is to make PainChek the universal pain assessment system for all people — adults and kids — and useable by every healthcare professional in all locations. We are on our way to achieving our ultimate goal — making pain a new healthcare vital sign,” CEO Philip Daffas said.

In terms of operational expenditure, cash outflow was $498,000 which mainly went towards staff and admin, and research and development costs.

At the end of the quarter, PainChek had $11.9 million in the bank.

Company shares are down 4.55 per cent and are trading at 6.3 cents at 10:55 am AEST.

PCK by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.